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Abstract
Background: Poor outcomes of invasive candidiasis (IC) are associated with the difficulty in establishing the
microbiological diagnosis at an early stage. New scores and laboratory tests have been developed in order to
make an early therapeutic intervention in an attempt to reduce the high mortality associated with invasive fungal
infections. Candida albicans IFA IgG has been recently commercialized for germ tube antibody detection (CAGTA).
This test provides a rapid and simple diagnosis of IC (84.4% sensitivity and 94.7% specificity). The aim of this study
is to identify the patients who could be benefited by the use of CAGTA test in critical care setting.
Methods: A prospective, cohort, observational multicentre study was carried out in six medical/surgical Intensive
care units (ICU) of tertiary-care Spanish hospitals. Candida albicans Germ Tube Antibody test was performed twice
a week if predetermined risk factors were present, and serologically demonstrated candidiasis was considered if the
testing serum dilution was ≥ 1:160 in at least one sample and no other microbiological evidence of invasive
candidiasis was found.
Results: Fifty-three critically ill non-neutropenic patients (37.7% post surgery) were included. Twenty-two patients
(41.5%) had CAGTA-positive results, none of them with positive blood culture for Candida. Neither corrected
colonization index nor antifungal treatment had influence on CAGTA results. This finding could corroborate that
the CAGTA may be an important biomarker to distinguish between colonization and infection in these patients.
The presence of acute renal failure at the beginning of the study was more frequent in CAGTA-negative patients.
Previous surgery was statistically more frequent in CAGTA-positive patients.
Conclusions: This study identified previous surgery as the principal clinical factor associated with CAGTA-positive
results and emphasises the utility of this promising technique, which was not influenced by high Candida
colonization or antifungal treatment. Our results suggest that detection of CAGTA may be important for the
diagnosis of invasive candidiasis in surgical patients admitted in ICU.
Background
Invasive candidiasis (IC), especially in the critical care
setting, has become an excellent target for prophylactic,
empiric, and pre-emptive therapy interventions due to
its increased incidence, high morbidity, mortality rate,
and associated healthcare costs [1,2]. Although the past
few years have brought exciting developments in anti-
fungal pharmacotherapy, the mortality rate remains
excessively high [3-7]. Poor outcomes are associated
with the difficulty in establishing the microbiological
diagnosis at an early stage of IC (blood culture results
are positive in only 50% and the antigen or antibody
detection also show low sensitivity rates at the present
time) [2] and the delay in receiving antifungal treatment
[8,9]. Moreover, it is well known that inadequate empiri-
cal antibiotic treatment is an independent determinant
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of hospital mortality and mycoses are among the types
of infection with the highest rates of inappropriate initial
treatment [10] and consequently worse prognosis [11].
New scores and laboratory tests have been developed
in order to make an early therapeutic intervention in an
attempt to reduce the high mortality associated with
invasive fungal infections [12,13]. Substantial progress
has been made in diagnosis of IC with the development
of a variety of methods for the detection of antibodies
and antigens. However, no single test has found wide-
spread clinical acceptance and there is a consensus that
diagnosis based on a single specimen lacks sensitivity
[14,15].
Candida albicans IFA IgG has been recently commer-
cialized for Candida albicans germ tube antibody
(CAGTA) detection. This test is based on the detection,
by an indirect immunofluorescence assay, of antibodies
against the surface of C. albicans germ tubes. The test
provides a rapid and simple diagnosis of IC in the clini-
cal microbiology laboratory (84.4% sensitivity and 94.7%
specificity) [16,17]. Although the performance of the test
has been studied in haematological patients (87.5% sen-
sitivity and 95.2% specificity) [18], no large clinical study
has been performed in the intensive care unit (ICU) set-
ting with this new tool. Two recently published mortal-
ity analyses of our group showed a significant decrease
of mortality in those patients with a CAGTA-positive
result in ICU patients [19,20], especially in those with
patterns of increasing CAGTA titres who had been trea-
ted with antifungal agents. Thus, antifungal treatment
should be considered when CAGTA titres increase in
critically ill patients [20]. However, the limitation of
these data, the complexity and the cost of this technique
make it mandatory to find which patients could be ben-
efit by the determination of CAGTA in order not to
apply this technique universally. For these reasons, the
aims of the present study were to determine the clinical
features of the patients with a CAGTA-positive result in
the ICU setting, in an attempt to define the population
of critically ill patients who could be benefit by this
technique analyzing the factors associated to a positive
result in order to make rentable the use of this test.
Methods
Patients and methods
During a two-year period (January 2005-December
2006) a prospective observational multicenter study was
conducted at six Spanish University hospitals: Hospital
Doctor Peset -HDP- (563 hospital beds/16 ICU beds,
Valencia), Hospital La Fe -HLF- (1,292/21, Valencia),
Hospital de Cruces -HDC- (931/18, Barakaldo), Hospital
Severo Ochoa -HSO- (365/12, Leganés), Hospital Reina
Sofía -HRS- (1,301/34, Córdoba), and Hospital Nuestra
Señora de Valme -HNSV- (639/14, Seville). The cohort
described is the same as has been previously published
by our group [19,20], but the data showed here are
novel and have not been included in our cited articles.
The institutional review boards at each participating
institution approved the study and informed consent
was obtained in each patient included in the study.
Study design and data collection
The study was developed following a pre-designed pro-
tocol with several predetermined analyses. A critically ill
patient was eligible for investigation and was enrolled in
the study if any of the following five inclusion criteria
were present: i) acute pancreatitis of more than seven
days of evolution; ii) prolonged ICU stay (>14 days) and
three or more risk factors (diabetes mellitus, extra-renal
depuration, parenteral nutrition, more than seven days
of broad spectrum antibiotic therapy, and major abdom-
inal surgery); iii) liver transplant; iv) neutropenia or
bone marrow transplant (BMT); and v) high Candida
colonization. Exclusion criteria were as follow: i) preg-
nancy; ii) younger than 18 years old, iii) previous IC; or
iv) life expectancy lower than seven days. Prior antifun-
gal therapy was not an exclusion criterion. All patients
were consecutively included in the study.
Severity of illness at inclusion of study was calculated
with the APACHE II score (Acute Physiology and
Chronic Health Evaluation). For all eligible patients,
screening cultures for Candida colonization were per-
formed weekly until seven days after ICU discharge.
These samples were obtained from bronchial aspirates,
oropharynx, urine, rectum, and peri-catheter skin as
part of the surveillance study. A corrected colonization
index (CCI) was used to assess the intensity of Candida
colonization [21-23], and patients with CCI ≥0.4 were
considered as highly colonized. J. Pemán and R. Zara-
goza reviewed all patients’ forms before including them
in the database.
Microbiological studies
CAGTA detection (Candida albicans IFA IgG, Vircell,
Spain) was performed twice a week. A positive result,
defined as serologically proven candidiasis, was consid-
ered when a serum titre ≥1:160 was detected in at least
one sample and no other microbiological evidence of IC
was found. Blood and sterile sites cultures were drawn
following physicians’ criteria and processed with auto-
mated systems (BACTEC, Becton Dickinson Diagnostic
Instrument Systems, Madrid, Spain or BacTAlert, bio-
Mérieux España, Madrid, Spain). Identification of yeasts
at species level was made with the API 20C, API 32C,
or the YST card of the Vitek system (bioMérieux
España, Madrid, Spain) at each institution. The decision
to add antifungal therapy for patients with suspected IC
was at the discretion of the prescribing physician based
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on clinical criteria, but it was not influenced by CAGTA
results (physicians had no access to the results). Clinical,
microbiological and outcome variables were recorded.
Data analysis
All quantitative data are presented as mean ± SD unless
otherwise stated. The chi-square or Fisher’s exact test
was used to compare categorical variables and student’s
t-test was applied for quantitative homocedastic vari-
ables with normal distribution. Two tailed p value of
0.05 or less was considered for statistical significance.
Data analysis was performed with the SPSS software for
Windows version 11.5 (SPSS, Chicago, IL). An external
statistical company assessed this analysis independently.
Results
Fifty-three miscellaneous critically ill patients were
included in the study, 37.7% of whom needed surgical
procedure during their stay in the ICU. The hospital
distribution of patients was as follows: 17 (HDC), 12
(HLF), 11 (HDP), 9 (HSO), 3 (HNSV) and 1 (HRS). The
most frequent patient inclusion criteria were prolonged
ICU stay and presence of ≥3 IC risk factors (60%) fol-
lowed by CCI ≥0.4 (23%), neutropenia or BMT (7.5%),
acute pancreatitis (6%) and liver transplant (4%). Five
patients (9%) presented extended ICU stay and ≥3 IC
risk factors plus high CCI. The age and APACHE II
score averages were 71.5 ± 18.4 years, and 14.9 ± 5.4
points, respectively. The principal causes of ICU admis-
sion were septic shock (28.3%) and respiratory failure
(28.3%), followed by post-surgery standard care (24.5%)
and coma (9.4%). The patient groups did not differ sig-
nificantly in demographic characteristics or inclusion
criteria among participating centres.
Culture-based methods yielded negative for blood and
sterile sites cultures for Candida spp. when where
drawn in all study patients. However, 43.3% of the
patients were highly colonized during the study.
Twenty-two patients (41.5%) had CAGTA-positive
results (10 patients had one positive sample, 8 had two,
and 4 had ≥3 positive determinations), none of them
with positive blood culture for Candida. The CAGTA
titres observed in these patients ranged from 1/160 to
1/2560. There were no differences between CAGTA-
positive and -negative patients in age, sex, inclusion
criteria, cause of admission, and presence of hepatic fail-
ure. The presence of acute renal failure at the beginning
of the study was more frequent in CAGTA-negative
patients, but no extra-renal depuration was needed.
APACHE II score was also statistically higher in this
group. Previous surgery was statistically more frequent
in CAGTA-positive patients in the univariate analysis
(Table 1). No statistical differences were found, in the
rate of highly colonized patients, between positive and
negative CAGTA results at the end of the study (77.2%
vs. 89.6%, respectively; p = 0.26).
Empiric antifungal treatment was applied in 50.9% of
cases during the study (after the inclusion); the regimens
most frequently prescribed were fluconazole (48.1%) and
voriconazole (14.8%). There was no difference in the
global administration of antifungal treatment between
CAGTA-positive and -negative patients (45.4% vs.
54.8%; p = 0.45); however, the use of voriconazole
showed a tendency to be more frequent in CAGTA-
positive patients (5.9% vs. 30%; p = 0.08) (Table 2).
Discussion
Mortality rates of IC episodes in the critical care setting
remain excessively elevated due to diagnosis difficulties
and, subsequently, inappropriate treatment. IC diagnosis
usually requires a high index of suspicion and is difficult
because the infection lacks pathognomonic signs, blood
cultures are often negative and, in many instances, it is
not possible to obtain specimens for histology; therefore,
serology could be an aid in its diagnosis, as it provides
specific biomarkers [2,24,25]. Demonstration of IC may
not be apparent because the infectious burden is
beneath the analytical sensitivity of the chosen diagnos-
tic modality, or infection remains limited in the context
of neutrophil recovery or follows administration of pro-
phylactic or empirical antifungal therapy. Serological
tests for the diagnosis of IC by detecting antibodies
against different antigens of Candida must differentiate
Candida colonization or superficial infection from tissue
invasion and candidemia requiring antifungal therapy.
Sera from patients with IC recognize a mannoprotein of
230-250 kDa located on the germ tube cell wall surface.
Pontón et al. [26,27] have developed an indirect immu-
nofluorescence assay to detect antibodies (CAGTA)
against this antigen present in C. albicans germ tubes,
which has been a useful biomarker for the diagnosis of
IC in different groups of patients, including intravenous
heroin users, BMT recipients, patients with haematolo-
gical disorders and ICU patients [16,18,28,29]. The test
has shown an overall sensitivity of 77-89% and a specifi-
city of 91-100%. Although the titres found in immuno-
compromised patients are lower than those found in
immunocompetent patients, the overall performance of
the test is similar. Detection of CAGTA in patients with
invasive infections caused by Candida species other
than C. albicans (Candida tropicalis, Candida parapsi-
losis, Candida glabrata, Candida dubliniensis, Candida
guilliermondii and Candida krusei) may also be positive,
although titers are lower than in candidiasis by C. albi-
cans [16,27,29-31].
Candida albicans IFA IgG has been recently commer-
cialized for CAGTA detection. This test has been com-
pared in a retrospective study to the standard test using
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172 sera from 51 haematological and intensive care
patients [16]. The commercially available test was simi-
lar to the standard test and provided faster and easier
diagnosis of IC in the clinical microbiology laboratory.
To our knowledge, this is the first time that the new
commercial kit for CAGTA detection has been studied
in the ICU setting. It is well known that the global sen-
sibility rate of blood culture is not too high (50%) in the
hospital population [32]. Moreover, this ratio is consid-
erable lower in the ICU setting as León et al. [12]
observed in the Candida score study, where the ratio of
proven IC was only 5.7%. However, until now this pro-
cedure is still the gold standard for candidemia diagno-
sis. The reasons for the low number of positive blood
cultures in critical care setting are unknown but are
likely to be related to the prophylactic and empiric
treatments administered to these patients [33,34]. In our
study, no blood cultures were positive. The low ratio of
positive blood cultures in critically ill patients obtained
in all studies in this setting, including this one, confirms
the compelling necessity of finding another sound gold
standard for validating new diagnostic tools [12,35,36].
Then, serological data may be used as evidence to impli-
cate Candida spp. when mycological and/or histological
data are negative or cannot be acquired. The high pre-
valence of CAGTA-positive results in the population
studied (41.5%) corroborates the adequacy of the inclu-
sion criteria used in this study as a predictive biomarker
of Candida infection and the need of consolidating the
CAGTA determination in a delimited group of ICU
population. For these reasons and for the excellent sen-
sitivity and specificity previously reported [16], all the
CAGTA-positive patients could be considered as “prob-
able” IC. The preliminary results presented in this study
Table 2 Distribution of antifungal treatment administered according to CAGTA results
No. of patients (%)
Total CAGTA + CAGTA - p value
Fluconazole 13 (48.1) 6 (60) 7 (41.2) 0.34
Voriconazole 4 (14.8) 3 (30) 1 (5.9) 0.08
Fluconazole + caspofungin* 4 (14.8) 0 4 (23.5) 0.09
Liposomal amphotericin B 2 (7.4) 0 2 (11.8) 0.25
Liposomal amphotericin B + fluconazole* 2 (7.4) 0 2 (11.8) 0.25
Caspofungin 1 (3.7) 0 1 (5.8) 0.43
Fluconazole + liposomal amphotericin B +caspofungin* 1 (3.7) 1 (10) 0 0.18
Total 27 (100) 10 (100) 17 (100) -
CAGTA: Candida albicans germ tube antibody.
*Sequential treatment.
Table 1 Main clinical characteristics of patients according to CAGTA results
No. of patients (%)
Total CAGTA + CAGTA - p value
Patients 53 22 (41.5) 31 (58.5) -
Age (years) 71.5 ± 18.4 69.2 ± 22.2 73.1 ± 15.3 0.46
Male:Female (ratio) 1.65 1.2 2.3 0.25
APACHE II (score) 14.9 ± 5.4 12.2 ± 4.4 16.9 ± 5.2 0.001
Septic shock 15 (28.3) 4 (18.2) 11 (35.4) 0.16
Respiratory failure 15 (28.3) 7 (31.8) 8 (25.8) 0.63
Coma 5 (9.4) 2 (9.1) 3 (9.7) 0.92
Renal failure 24 (45.3) 6 (27.3) 18 (58.1) 0.02
Extra-renal depuration 16 (30.2) 4 (18.2) 12 (38.7) 0.1
Hepatic failure 19 (35.8) 9 (40.9) 8 (25.8) 0.24
Neutropenia 4 (7.5) 0 4 (12.9) 0.1
Broad spectrum antibiotics 36 (67.9) 17 (77.3) 19 (61.3) 0.21
Parenteral nutrition 33 (62.3) 14 (63.7) 19 (61.3) 0.86
Hepatic transplant 2 (3.8) 1 (4.5) 1 (3.2) 0.80
Acute pancreatitis 3 (5.7) 2 (9.1) 1 (3.2) 0.36
Diabetes mellitus 12 (22.6) 4 (18.2) 8 (25.8) 0.51
Previous surgery 20 (37.7) 12 (54.5) 8 (25.8) 0.03
CAGTA: Candida albicans germ tube antibody.
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evidence the need for a large multicentre study to vali-
date the CAGTA detection as an alternative diagnosis
tool in the ICU setting [16,30].
This study identifies the principal risk factors asso-
ciated with serological proven candidiasis (Table 1) and,
probably, with hidden invasive Candida infection in the
ICU population due to the absence of other microbiolo-
gical positive tests. Only previous surgery was statisti-
cally more frequent in patients with CAGTA-positive
results. Furthermore, in our study previous surgery is a
determinant risk factor for candidemia as has been
described by León et al. [12]; however, although diabetes
mellitus has been previously described as a risk factor
for developing IC in critically ill patients [37], our find-
ings do not support the inclusion of diabetes mellitus in
clinical scores to predict IC in ICU patients. Recently
published clinical scores such as the “Candida score”
[12] or the Ostrosky-Zeichner et al. rule [38] have not
included this risk factor. Consequently, periodical
CAGTA determination should be mandatory especially
in ICU surgical patients to achieve an early diagnosis
and, therefore, to improve the candidemia prognosis,
especially in those patients with patterns of increasing
CAGTA titres [20]. This assay could improve the pre-
dictor value of these previously described prediction
scores and rules.
The rate of highly colonized patients was very high as
has been previously described [39] and no statistical dif-
ferences were found between CAGTA-positive and
-negative patients at the end of the study. This finding
could corroborate the CAGTA technique as a key bio-
marker to distinguish between colonization and infec-
tion in these patients.
In our study, the decision to add empiric antifungal
therapy for patients with suspected IC was at the discre-
tion of the prescribing physician based on clinical cri-
teria, but was never guided by CAGTA results. The no
difference observed neither the global administration of
antifungal treatment nor antifungal agent used between
CAGTA-positive and -negative give more value to this
technique avoiding false-negative results in presence of
any antifungal therapy.
Several limitations must be noted in this study. First,
the small number of patients due to the difficulty to
enrol this kind of patients with predefined criteria.
Moreover, there was no possibility to establish the sensi-
bility and specificity of CAGTA technique due to the
absence of microbiological and histological documenta-
tion of IC in this study.
Conclusions
This study identified previous surgery as the principal
clinical factor associated with CAGTA-positive results
(serologically proven candidiasis) and emphasises the
utility of this promising technique, which was not influ-
enced by high Candida colonization or antifungal treat-
ment. For these reasons the addition of the CAGTA
technique to the armamentarium for the diagnosis of IC
in surgical patients admitted in ICU would be a great
advantage as it could help to identify hidden invasive
Candida infection in the surgical ICU population with a
long stay in this setting.
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